Clinical trialPhase 1Not yet recruiting
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
A Pilot Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 1 September 2026
- Expected end
- 30 September 2032
- Enrollment
- 25 participants
- Sites
- 1
- Primary outcomes
- Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotype
- Sponsor
- Other
- Results posted
- No
- Last update
- 5 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..
Detailed description public domain (ClinicalTrials.gov)
The aim of this study is to evaluate the mechanism of action for a novel anti-Netrin-1 antibody (NP137) in patients with pancreatic ductal adenocarcinoma. Pre-clinical data indicates that anti-Netrin-1 therapy can prevent/delay metastatic progression of disease by inducing cancer cell death through its dependence receptor Unc5b as well as prevent epithelial to mesenchymal transition (EMT). This pilot study is designed to provide vital translational scientific information that will inform the design of future clinical trials for NP137. This information includes determining the optimal use of NP137 with cytotoxic, as well as the treatment setting of resectable pancreatic cancer.